M&T Bank
RPRX icon

M&T Bank’s Royalty Pharma RPRX Stock Holding History

M&T Bank’s Portfolio RPRX Stock Details RPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.5M Sell
26,746
-489
-2% -$25.5K ﹤0.01% 732
2026
Q1 		$1.31M Sell
27,235
-1,026
-4% -$44.9K ﹤0.01% 741
2025
Q4 		$1.09M Buy
28,261
+5,199
+23% +$198K ﹤0.01% 828
2025
Q3 		$813K Sell
23,062
-2,754
-11% -$99.7K ﹤0.01% 834
2025
Q2 		$930K Sell
25,816
-3,151
-11% -$104K ﹤0.01% 868
2025
Q1 		$902K Buy
28,967
+5,500
+23% +$174K ﹤0.01% 857
2024
Q4 		$599K Buy
23,467
+4,718
+25% +$125K ﹤0.01% 1100
2024
Q3 		$531K Buy
18,749
+779
+4% +$21.6K ﹤0.01% 1143
2024
Q2 		$474K Buy
17,970
+483
+3% +$13.4K ﹤0.01% 1132
2024
Q1 		$532K Sell
17,487
-1,043
-6% -$30.7K ﹤0.01% 1125
2023
Q4 		$520K Buy
18,530
+2,175
+13% +$59.8K ﹤0.01% 1117
2023
Q3 		$444K Buy
16,355
+1,702
+12% +$50.6K ﹤0.01% 1135
2023
Q2 		$451K Buy
14,653
+423
+3% +$14.3K ﹤0.01% 1170
2023
Q1 		$513K Sell
14,230
-4,559
-24% -$169K ﹤0.01% 1101
2022
Q4 		$743K Buy
18,789
+8,118
+76% +$339K ﹤0.01% 958
2022
Q3 		$428K Buy
10,671
+259
+2% +$11.1K ﹤0.01% 1151
2022
Q2 		$437K Buy
10,412
+3,119
+43% +$128K ﹤0.01% 1066
2022
Q1 		$283K Sell
7,293
-3,598
-33% -$141K ﹤0.01% 1227
2021
Q4 		$433K Buy
10,891
+23
+0.2% +$894 ﹤0.01% 1088
2021
Q3 		$393K Sell
10,868
-1,923
-15% -$74.7K ﹤0.01% 1118
2021
Q2 		$524K Buy
12,791
+526
+4% +$22.4K ﹤0.01% 1013
2021
Q1 		$535K Buy
12,265
+3,641
+42% +$173K ﹤0.01% 963
2020
Q4 		$431K Buy
+8,624
New +$366K ﹤0.01% 1134

Other funds holding RPRX

Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

M&T Bank's RPRX Position: Q2 2026 in Review

M&T Bank reduced its Royalty Pharma (RPRX) stake by 1.8% in Q2 2026, selling an estimated $25.5K and leaving 26,746 shares worth $1.5M. The position accounts for ﹤0.01% of the portfolio, ranked #732.

M&T Bank first reported a position in RPRX in Q4 2020 and has held it in 23 quarters since. 641 funds tracked by Wall St. Rank hold RPRX as of Q2 2026.

  • M&T Bank held 26,746 shares of Royalty Pharma worth $1.5M as of Q2 2026.
  • M&T Bank sold 489 Royalty Pharma shares in Q2 2026, an estimated $25.5K.
  • Royalty Pharma made up ﹤0.01% of M&T Bank's portfolio in Q2 2026, its #732 holding.
  • M&T Bank first reported a position in Royalty Pharma in Q4 2020 and has held it in 23 quarters since.
  • 641 funds tracked by Wall St. Rank held Royalty Pharma as of Q2 2026.

Based on M&T Bank's 13F filing for Q2 2026, filed 4 Aug 2026.